Should Only Patients with BRCA Mutation Be Treated with a Combination of an Androgen Receptor Pathway Inhibitor and a PARP Inhibitor for Metastatic Castration-resistant Prostate Cancer? The Answer Is No
European Urology Focus · 2024
DOI: 10.1016/j.euf.2024.07.015 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Urology Focus, 2024. Verfasst von Fred Saad. Beteiligte Einrichtung: Department of Surgery, University of Montreal Hospital Center, Montreal, Canada. Electronic address: fred.saad@umontreal.ca. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Prostatic Neoplasms, Castration-Resistant, Androgen Receptor Antagonists, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
Patients who benefit the most from combinations of an androgen receptor pathway inhibitor and a PARP inhibitor are those with a BRCA mutation, but there are certainly patients without BRCA mutations who will benefit from this treatment strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, University of Montreal Hospital Center, Montreal, Canada. Electronic address: fred.saad@umontreal.ca.
Zitieren
APA
Saad, F. (2024). Should Only Patients with BRCA Mutation Be Treated with a Combination of an Androgen Receptor Pathway Inhibitor and a PARP Inhibitor for Metastatic Castration-resistant Prostate Cancer? The Answer Is No. European Urology Focus. https://doi.org/10.1016/j.euf.2024.07.015
Vancouver
Saad F. Should Only Patients with BRCA Mutation Be Treated with a Combination of an Androgen Receptor Pathway Inhibitor and a PARP Inhibitor for Metastatic Castration-resistant Prostate Cancer? The Answer Is No. European Urology Focus. 2024. doi:10.1016/j.euf.2024.07.015
BibTeX
@article{Saad2024,
author = {Saad, Fred},
title = {Should Only Patients with BRCA Mutation Be Treated with a Combination of an Androgen Receptor Pathway Inhibitor and a PARP Inhibitor for Metastatic Castration-resistant Prostate Cancer? The Answer Is No},
journal = {European Urology Focus},
year = {2024},
doi = {10.1016/j.euf.2024.07.015}
}
EUVIMED